Pharvaris NV
PHVS25.120USD
+5.290+26.68%
종가 07/11, 16:00（ET）시세는 15분 지연됩니다
1.37B시가총액
손실P/E TTM
자세한 내용은 Pharvaris NV 회사
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
회사 정보
종목 코드 PHVS
회사 이름Pharvaris NV
상장일Feb 05, 2021
설립일2015
CEOMr. Berndt Modig, CPA
직원 수- -
유형Ordinary Share
회계 연도 종료Feb 05
주소Emmy Noetherweg 2
도시LEIDEN
증권 거래소NASDAQ Global Select Consolidated
국가Netherlands
우편 번호2333 BK
전화31712036410
웹사이트https://pharvaris.com/
종목 코드 PHVS
상장일Feb 05, 2021
설립일2015
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Thu, May 15
마지막 업데이트: Thu, May 15
주주
주주 유형
주주
주주
비율
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
주주
주주
비율
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
주주 유형
주주
비율
Private Equity
30.24%
Investment Advisor
18.67%
Venture Capital
17.96%
Hedge Fund
15.17%
Investment Advisor/Hedge Fund
7.22%
Individual Investor
6.25%
Research Firm
0.15%
Bank and Trust
0.05%
Pension Fund
0.04%
Other
4.26%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
124
52.17M
95.74%
-1.39M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
2023Q1
61
28.67M
84.75%
-3.62M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
General Atlantic LLC
7.53M
13.82%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.40M
9.9%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
4.41M
8.09%
+12.70K
+0.29%
Mar 31, 2025
VenBio Partners LLC
4.29M
7.87%
--
--
Mar 31, 2025
Viking Global Investors LP
3.65M
6.7%
--
--
Mar 31, 2025
EQT Life Sciences
3.56M
6.53%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
6.06%
--
--
Mar 31, 2025
VR Adviser, LLC
3.11M
5.71%
-107.41K
-3.34%
Mar 31, 2025
Deerfield Management Company, L.P.
2.02M
3.7%
--
--
Mar 31, 2025
Commodore Capital LP
1.91M
3.51%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
이름
비율
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
ALPS Medical Breakthroughs ETF
0.73%
iShares MSCI Netherlands ETF
0.1%
iShares MSCI Europe Small-Cap ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares MSCI EAFE Small-Cap ETF
0.01%
Avantis International Small Cap Equity ETF
0.01%
First Trust IPOX Europe Equity Opportunities ETF
0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.96%
ALPS Medical Breakthroughs ETF
비율0.73%
iShares MSCI Netherlands ETF
비율0.1%
iShares MSCI Europe Small-Cap ETF
비율0.02%
SPDR S&P International Small Cap ETF
비율0.02%
iShares MSCI EAFE Small-Cap ETF
비율0.01%
Avantis International Small Cap Equity ETF
비율0.01%
First Trust IPOX Europe Equity Opportunities ETF
비율0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
